In recent years, telehealth technology has been more readily available and effective in connecting providers and patients. Jennifer Raymond, MD, MCR, will make the case for using telehealth in psychological care, while Michael A. Harris, PhD, will make the case for more research into telehealth models before wide adoption for this kind of care.

Sarah C. Westen will explain what the Psychosocial Subcommittee of the Youth Strategies Committee has accomplished over the past two years. She will share videos created by the team as well as strategies to help improve communication between health care teams and children and their families.

“Sip & Chat” with Alice Cheng, MD, FRCPC, and Michael Natter, MD, on Sunday in the Exhibit Hall. Dr. Cheng, co-host of the Diabetes Care “On Air” podcast and Scientific Sessions Meeting Planning Committee Chair, will interview Dr. Natter, a visual artist and endocrinologist, on how his artistic eye influenced his medical practice.

As the 83rd Scientific Sessions got underway at the San Diego Convention Center, attendees gathered in the Exhibit Hall on Friday evening for a Networking Reception with exhibitors. In addition to providing an opportunity to engage with industry leaders, the event offered a preview of the Poster Hall and a venue to connect with friends…

Francis S. Collins, MD, PhD, who led the Human Genome Project, welcomed attendees to the 83rd Scientific Sessions with a message about the potential of omics data to drive new avenues of research into complex diseases like diabetes. Already, genome-wide association studies take information about common variations in the genome to identify statistically significant differences…

Pathway to Stop Diabetes® researchers, including Aleksandar D. Kostic, PhD, presented their new approaches for working toward a cure for this pervasive disease. These investigators are looking at the gut microbiome, cloaked beta-cells, branched-chain amino acid, dysregulation of the gut-brain axis by sugar, and diabetes distress with new perspectives with funding from the American Diabetes…

Therapeutic inertia is a common problem in managing type 2 diabetes. Experts including Kevin M. Pantalone, DO, ECNU, FACE, addressed how it can be prevented, such as achieving A1C targets within a year of treatment, leveraging the entire health care team in the patient’s journey, and having accessibility to the patient’s electronic health record.

New to the Scientific Sessions lineup, the Innovation Challenge invites six contestants to pitch their concepts for improving the lives of people living with diabetes before a panel of potential funders. Three finalists will earn a private audience with the judges, explained ADA Chief Scientific and Medical Officer Robert Gabbay, MD, PhD.

A panel including Ellen Leschek, MD, will discuss teplizumab clinical trial results and the role of the CD3-directed monoclonal antibody in delaying the progression from stage 2 type 1 diabetes to stage 3. Joining Dr. Lesheck will be researchers, clinicians, and a patient with type 1 diabetes.

Michael J. Haller, MD, and Antionette Moran, MD, will present data and arguments in support of technology and immunomodulation, respectively, in treating patients with type 1 diabetes. Dr. Haller said most experts likely agree there will be a role for both going forward and each should be discussed and offered to patients.